Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Untch

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trialS Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)G von Minckwitz, M Rezai, P A Fasching, et al.
ESMO Open|November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)T Link, M Reinisch, M Just, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialC E Geyer, W M Sikov, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trialS Loibl, C Jackisch, A Schneeweiss, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)G von Minckwitz, M Rezai, P A Fasching, et al.
ESMO Open|November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)T Link, M Reinisch, M Just, et al.
British Journal of Cancer|August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trialI Witzel, S Loibl, G von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)G von Minckwitz, M Rezai, H Tesch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosisM Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trialC E Geyer, W M Sikov, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapyJ L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgeryM Untch, P A Fasching, G E Konecny, et al.
Pageof 17